An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.

U.S. News & World Report consistently ranks the Mass General Cancer Center as one of the top ten cancer centers in the country. Its nurses were the first in Massachusetts to achieve Magnet status from the American Nurses Credentialing Center in recognition of the hospital’s exceptional nursing care.

Known for providing customized, innovative treatments and compassionate care to both adults and children, the Cancer Center comprises 24 fully integrated, multidisciplinary clinical programs and a vast array of support and educational services. Its network of affiliations extends throughout New England and the southeastern U.S.

The Cancer Center’s commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.

The Massachusetts General Hospital Cancer Center is proud to be a founding member of a Harvard Medical School consortium designated by the National Cancer Institute as a comprehensive cancer center. This prestigious seven-member center forms the largest cancer research collaboration in the country. The promising new treatments developed through this partnership are revolutionizing the future of cancer medicine. For more information click here.

Darrell Borger, PhD, Massachusetts General Hospital

My primary focus at the Massachusetts General Hospital is to assist in the development of the Translational Research Laboratory, as co-director. Our goal is to develop and employ innovative technologies to genotypically fingerprint patient tumors across the complete spectrum of … read more ❯

Lecia Sequist, Massachusetts General Hospital (MGH)

Dr. Sequist and her colleagues at MGH have been at the forefront of research in EGFR mutations: her group was among the first to identify activating mutations and observe the correlation with response to EGFR tyrosine kinase inhibitors (TKIs), and … read more ❯